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Introduction {#s1}
============

Prevalence of skin cancer has increased in recent decades and its public health burden has also grown alongside ([@R1],[@R2]). Although mortality rate from skin cancer is relatively low, it can cause a great deal of morbidity instead, emphasising its public health importance ([@R3]). It has been suggested therefore that skin cancer will play an important part in the global burden of disease in the next decade ([@R4]).

There are three major types of skin cancer ([@R2],[@R3]). Basal cell carcinoma is the most common type of skin cancer. Squamous cell carcinoma is in the second place. It is less prevalent than the basal cell type but it can cause more tissue damage as the tumour usually invades the adjacent tissue and therefore is more aggressive ([@R3]). Malignant melanoma is the third common skin cancer type. It was once very rare about 50 years ago but its prevalence has since increased considerably ([@R3]). Although it only comprises 3% of all skin cancer types, it is still responsible for 75% of deaths due to skin cancer ([@R5]).

Skin cancer is an important health problem in Iran. According to Iranian National Cancer Registry 2003-2007 reports it is the most common cancer type in men. In women it is the second most prevalent type of all cancers. When we put data for men and women together it still holds the first place among the most common cancer types in Iranian population ([@R6]-[@R13]).

Estimating survival rate and factors associated with it is an important first step in any effective program aimed at decreasing the overall burden of any type of cancer. Knowledge of 3 or 5 years survival rates could also help in provision of healthcare in these patients as understandably they will have particular needs during this period. We have therefore studied survival rates of skin cancer in Kurdistan province of Iran and its associated factors using data from Kurdistan cancer Registry.

Methods {#s2}
=======

In this retrospective cohort study that was conducted in 2010 we identified all patients registered with Kurdistan Cancer Registry as having any type of skin cancer between years 2000 and 2009 and extracted all their demographic and tumour related information. We then contacted all those who had a telephone number recorded in their files and willing to participate that comprised about half of the registered skin cancer population and entered them into the study. Characteristics of study subjects were compared with the rest of the registered skin cancers. Through linkage with Registrar's provincial office information on date and cause of death for study subjects were obtained and their vital status double checked when contacted. A telephone interview was carried out with the patient if s/he was alive or with a close relative in case the patient had passed away. Those we could not reach at our first try were contacted twice more at different times.

We used a two-part questionnaire for our data collection. The first part was completed using the available data at the cancer registry. The second part was filled during the telephone interview with the patients or their first degree relatives.

In addition to their vital status, questions were asked about a list of factors that are potentially associated with survival. These factors included age, sex, tumour type, anatomic location of the tumour, place of residence, any report of delay in diagnosis of cancer, tumour stage, and educational level of the patients. Delay in diagnosis was defined as the time between first appearance of symptoms and the definitive diagnosis of skin cancer. Anatomical locations of the tumours were categorised according to the Iranian National Registry guidelines.

Tumour stage was determined using the TNM system (according to the seventh edition of the American Joint Committee on Cancer (AJCC). AJCC-7 Cancer Staging Manual includes a major revision of the staging protocol for cutaneous carcinomas ([@R14]). T stands for tumour and defines the size of the lesion; N stands for lymph nodes and describes the degree of involvement of the adjacent lymph nodes; and M stands for metastasis and explains whether the tumour has reached other parts of body. Based on the above three dimensions tumours are divided into 5 stages ([Table 1](#T1){ref-type="table"}). When the staging information were absent in registry records, data were collected from hospitals' files where possible.

###### Tumour and patient characteristics by tumour type

  ----------------------------- ------------------------------ ------------- ------------ ------------ ------------ -------------
  Variable                                                     BCC           SCC          MM           Other        Total
  Age(year)                                                    N‏(%)         N‏(%)        N‏(%)        N‏(%)        N‏(%)
                                \<60                           128(41.4%‏)   28(26%‏)     4(30.8%‏)    20(46.5%‏)   180(38%)
                                60-79                          134(43.4%‏)   59(55%‏)     7(53.8%‏)    17(39.5%‏)   217(46%‏)
                                \>=80                          47(15.2%‏)    20(18.7%‏)   2(15.4%‏)    6(14%‏)      75(16%‏)
                                Total                          309(100%‏)    107(100%‏)   13(100%‏)    43(100%‏)    472(100%‏)
  Sex                           Male                           190(61.5%‏)   82(76.6%‏)   6(46.2%‏)    25(58%‏)     303(64%‏)
                                Female                         119(38.5%‏)   25(23.4%‏)   7(53.8%‏)    18(‏(42%)    169(36%‏)
                                total                          309(100%‏)    107(100%‏)   13(100%‏)    43(100%‏)    472(100%‏)
  Place of residence            Urban                          223(72.2%‏)   61(57%‏)     12(92.3%‏)   29(67.5%‏)   325(69%‏)
                                Rural                          86(27.8%‏)    46(43%‏)     1(7.7%‏)     14(32.5%‏)   147(31%‏)
                                Total                          309(100%‏)    107(100%‏)   13(100%‏)    43(100%‏)    472(100%‏)
  Tumour anatomic site          Face                           257(83.5%‏)   66(62.3%‏)   3(23%‏)      16(37%‏)     342(73%‏)
                                scalp and neck                 25(8%‏)       8(7.5%‏)     1(7.7%‏)     3(7%‏)       37(8%‏)
                                Trunk                          4(1.3%‏)      3(2.8%‏)     0            9(21%‏)      16(3.5%‏)
                                Upper extremity and shoulder   2(0.7%‏)      6(5.7%‏)     0            3(7%‏)       11(2%‏)
                                Lower extremity and hip        0             6(5.7%‏)     9(69.2%‏)    8(18.6%‏)    23(5%‏)
                                Multiple sites                 2(0.7%‏)      5(4.7%‏)     0            2(4.7%‏)     9(2%‏)
                                Face & scalp and neck          4(1.3%‏)      2(1.9%‏)     0            1(2.3%‏)     7(1.5%‏)
                                External ear                   14(4.5%‏)     10(9.4%‏)    0            1(2.3%‏)     25(5%‏)
                                Total                          308(100%‏)    106(100%‏)   13(100%‏)    43(100%‏)    470(100%‏)
  Stage                         StageI& Stage II               11(64.7%‏)    5(18.5%‏)    4(50%‏)      2(22.2%‏)    22(36%‏)
                                Stage III                      4(23.5%‏)     5(18.5%‏)    0            0            9(14.8%‏)
                                Stage IV                       2(11.8%‏)     17(63%‏)     4(50%‏)      7(77.8%‏)    30(49.2%‏)
                                Total                          17(100%‏)     27(100%‏)    8(100%‏)     9(100%‏)     61(100%‏)
  Delay in diagnosis (month‏)   \<=24                          229(80.4%‏)   86(89.6%‏)   12(92.3%‏)   31(81.6%‏)   358(83%‏)
                                25-48                          32(11.2%‏)    5(5.2%‏)     1(7.7%‏)     5(13.2%‏)    43(10%‏)
                                49-72                          14(4.9%‏)     3(3%‏)       0            0            17(4%‏)
                                \>=73                          10(3.5%‏)     2(2%‏)       0            2(5.2%‏)     14(3%‏)
                                Total                          285(100%‏)    96(100%‏)    13(100%‏)    38(100%‏)    432(100%‏)
  Educational level             Illiterate                     189(63.9%‏)   72(74%‏)     10(76.9%‏)   25(62.5%‏)   296(66.4%‏)
                                Below diploma                  76(25.7%‏)    23(23.7%‏)   2(15.4%‏)    9(22.5%‏)    110(24.6%‏)
                                =\>Diploma                     31(10.5%‏)    2(2%‏)       1(7.7%‏)     6(15%‏)      40(9%‏)
                                Total                          296(100%‏)    97(100%‏)    13(100%‏)    40(100%‏)    446(100%‏)
  ----------------------------- ------------------------------ ------------- ------------ ------------ ------------ -------------

We collected data on time and cause of death from both the relatives and the Kurdistan Provincial Registrar Office. In case of any discrepancy between the two, the family of the patients was contacted directly in urban areas and indirectly via rural health center officers (Behvarz) in rural areas in order to obtain accurate information.

Statistical analysis was conducted using SPSS 18. Survival analysis methods including Kaplan Meier and log rank tests were used to compare the survival experience in different patient categories. Cox proportional hazard regression model was used to account of the potential confounding variables. Hazard ratios and their 95% confidence interval were calculated. Proportional hazard assumption was checked for every model using log minus log plot.

Results {#s3}
=======

There were 1353 registered patients of which, telephone contact details were available for 667. A total of 472 interviews were conducted and the remaining 195 patients could not be reached for a variety of reasons including change of address (24 cases), wrong number (84 cases), closure of line (28 cases), and finally 59 cases did not respond to the calls. Average follow up time was 34 months. A total of 78 deaths were detected of which 44 was due to skin cancer. Study subjects had similar characteristics to the rest of the registered skin cancers ([Table 4](#T4){ref-type="table"}).

Of 472 cases that were analysed, 64% were men and 62% were over 60 years old. Mean and median ages of the subjects were 64 and 65 years, respectively. According to tumour histological type, 66% had basal cell carcinoma, 23% had squamous cell carcinoma, 3% malignant melanoma, and the remaining 8% had other types of skin tumours. 36% of tumours had been diagnosed in stage I and II, 15% in stage III and 49% in stage IV ([Table 1](#T1){ref-type="table"}).

One, two and five years survival rates were 96%, 91.6, and 85%, respectively. There were only 3 cases of deaths in basal cell carcinoma patients that were attributable to their skin cancer. Three- year survival rate for squamous cell carcinoma was 67% and for malignant melanoma 50%.

In univariate analysis age, place of residence, education, tumour anatomical location, type and diseases stage were all significantly associated with survival. Risk of death increased with age and was higher in women than in men but the difference did not reach statistical significance. People living in rural areas died twice as faster as their urban counterparts. Regarding the anatomical location, facial lesions carried the lowest risk and involvement of multiple body site the highest risk of death. Squamous cell carcinoma and malignant melanoma patients died 33.6 (95% CI 10.3-110.6) and 27.2 (95% CI 5.5-135.5) faster than patients having basal cell carcinomas that carried the lowest risk. Stage of the tumour was also significantly associated with survival. Risk of death increased with the increase in the tumour stage. Stages I and II carried the lowest risk. Risk of death in stage III was 3 (95% CI 0.5-18.6) times and in stage IV 10.8 (95% CI 2.6-46.2) times higher compared to the stages I and II ([Table 2](#T2){ref-type="table"}).

###### Characteristics associated with survival in univariate analysis

  ----------------------------- ------------------------------ ----- ------- --------------------------
  Variables                                                    No.   Event   Hazard Ratios and 95% CI
  Age (year‏)                   60\>                           180   7       Reference
                                60-79                          217   23      2.95 (1.3-6.8)
                                \>=80                          75    14      6.29 (2.6-15.63)
                                Total                          472   44      Log Rank test, P\<0.001
  Sex                           Male                           303   29      Reference
                                Female                         169   15      1.03 (0.55-1.9)
                                Total                          472   44      Log Rank test, P=0.07
  Place of residence‏,          Urban                          325   24      Reference
                                Rural                          147   20      2.05 (1.21-3.71)
                                Total                          472   44      Log Rank test, P=0.01
  Anatomic site                 Face                           342   24      Reference
                                Scalp and neck                 37    3       1.07 (0.32-3.5)
                                Trunk                          16    1       1.15 (0.15-8.5)
                                Upper extremity and shoulder   11    1       1.64 (0.22-12)
                                Lower extremity and hip        23    7       5.27 (2.3-12.3)
                                Multiple sites                 9     4       9.36 (3.3-24.3)
                                Face & scalp and neck          7     1       1.55 (0.3-11.5)
                                External ear                   25    2       1.1 (0.3-4.7)
                                Total                          470   43      Log Rank test, P\<0.001
  Type of tumor                 BCC                            309   3       Reference
                                SCC                            107   29      33.66 (10.3-110.6)
                                MM                             13    3       27.2 (5.5-135.5)
                                Others                         43    9       25.8 (7-95.5)
                                Total                          472   44      Log Rank test, P\<0.001
  Stage                         Stage I and II                 22    2       Reference
                                Stage III                      9     3       3.1 (0.5-18.6)
                                Stage IV                       30    23      10.85 (2.6-46.2)
                                Total                          61    28      Log Rank test, P\<0.001
  Delay in diagnosis (month‏)   \<=24                          358   25      Reference
                                25-48                          43    5       1.74 (0.7-4.6)
                                49-72                          17    3       2.4 (0.8-7.9)
                                \>=73                          14    2       2 (0.5-7.5)
                                total                          432   35      Log Rank test, P=0.300
  Educational level             illiterate                     296   30      Reference
                                below diploma                  110   4       0.33 (0.2-0.9)
                                =\>Diploma                     40    1       0.22 (0.03-1.6)
                                total                          446   35      Log Rank test, P=0.02
  ----------------------------- ------------------------------ ----- ------- --------------------------

Cox proportional hazard model was built to account for the possible confounding effects of existing variables. The three variables of tumour type, stage and anatomical location remained significant in the model and were independently associated with survival ([Table 3](#T3){ref-type="table"}). In model checking, there was not a serious violation of the proportional hazard assumption.

###### Variables predicting survival in the final Cox proportional hazard model

  ----------------- ------------------------------ --------- --------------- ------------------------- --------
  Variables         subgroups                      p-value   Hazard Ratios   95% confidence interval   

  Tumor stage       stage I and II                 0.040     Reference       Lower                     Higher

                    stage III                      0.044     16.8            1.07                      260.2

                    stage IV                       0.014     16.7            1.8                       156.6

  Tumor type        Bcc                            0.023     Reference                                 

                    Scc                            0.002     74.5            4.8                       1146.7

                    Mm                             0.036     24.4            1.3                       485

                    Other                          0.013     77              2.5                       2412.8

  Tumor\            Face                           0.170     Reference                                 
  Anatomical site                                                                                      

                    scalp and neck                 0.033     48.6            1.4                       1714.5

                    Trunk                          0.098     0.000                                     0

                    Upper extremity and shoulder   0.628     0.6             0.05                      6.3

                    Lower extremity and hip        0.676     0.7             0.2                       3.7

                    Multiple sites                 0.437     0.6             0.09                      2.8

                    Face+scalp and neck            0.256     0.2             0.006                     3.9

                    External ear                   0.017     0.09            0.011                     0.7
  ----------------- ------------------------------ --------- --------------- ------------------------- --------

###### Comparing some characteristics of interviewed subjects with the rest of the skin cancers registered in Kurdistan Cancer Registry from year 2000 to 2009

  ----------------- ------------------- ------------------------------------- ----------------
                                        Rest of the registered skin cancers   Study subjects
  Age                                   N(%)                                  N(%)
                    below 60 years      295(33.6%)                            180 (38%)
                    60-79 years         482(54.8%)                            217 (46%)
                    80 years and over   102(11.6%)                            75(16%)
                    total               879(100%)                             472(100%)
  Sex                                                                         
                    Male                522(59%)                              303(64%)
                    Female              359(41%)                              169(36%)
                    total               881(100%)                             472(100%)
  Tumor type                                                                  
                    BCC                 578(66%)                              309(65%)
                    SCC                 220(25%)                              107(23%)
                    MM                  21(2%)                                13(3%)
                    Others              62(7%)                                43(9%)
                    total               881(100%)                             472(100%)
  Anatomical site                                                             
                    Face                612(74%)                              342(73%)
                    Head and neck       81(10%)                               37(8%)
                    Trunk               41(5%)                                16(3.5%)
                    Upper extremities   22(3%)                                11(2%)
                    Lower extremities   37(4%)                                23(5%)
                    Multiple site       0(0%)                                 9(2%)
                    Face and neck       4(1%)                                 7(1.5%)
                    External ear        27(3%)                                25(5%)
                    total               824(100%)                             470(100%)
  ----------------- ------------------- ------------------------------------- ----------------

Discussion {#s4}
==========

We found that the survival figures are relatively low in Kurdistan province compared to similar international studies. One, two and 5 years survival rates for all skin cancer were 96%, 91.6% and 85%. In squamous cell cancer the three-years survival rate was 67% and the corresponding figure for malignant melanoma was 50%. Age, place of residence, education, tumour anatomical location, type and stage were associated with survival in univariate analysis. However after controlling for the possible confounding factors, type, anatomical location and stage of the tumour were the significant predictors of survival.

Our findings regarding the survival rates for squamous cell carcinoma and malignant melanoma show that the survival rates in Kurdistan province is relatively low. In a prospective study on patients having squamous cell carcinoma in Texas, USA, three years survival rate was found to be 85% ([@R15]). This figure for most European countries is around 90% ([@R16]). Other reports from Europe estimates the 5-year survival rate of melanoma at around 70% ([@R17]) and in the United States the 5-year survival were 86.8% and 92.0 in men and women ([@R18]). In another review study, survival rates for malignant melanoma were 78% and 91% in men and women respectively ([@R19]). Our findings, therefore, of a 5 years survival of 50% for malignant melanoma indicate a significant gap with the international figures. A possible explanation for this finding is the late diagnosis (in stage III or IV) of the tumour that makes an effective treatment unlikely. Our finding that anatomical location of the tumour is an independent predictor of survival is in agreement with most of the literature on this subject. Studies from Netherlands ([@R20]), California USA ([@R21]), and United States ([@R16]) all showed that anatomical location of tumour is significantly associated with survival. Variation in survival according to the anatomical location of the tumour may result from a variation in tumour invasive behaviour in different body sites.

Our study showed that tumour type is an important predictor of survival ([Fig.1](#F1){ref-type="fig"}). The difference originates from the tumour invasive behaviour and its ability to send distant metastasis. In our current study survival experience of patients with squamous cell carcinoma were worse than those having malignant melanoma while in other studies usually worst survival belongs to malignant melanoma. In a study from Denmark ([@R22]) and a retrospective cohort analysis ([@R23]) in general, relative survival after basal cell carcinoma was better than after squamous cell carcinoma.

![](MJIRI-29-277-g001){#F1}

In many countries mortality rates for non-melanoma skin cancer is very low ([@R1]). The possible explanation for our finding is the late diagnosis of patients having squamous cell carcinoma. While 50% of melanoma tumours were in stages I and II at the time of diagnosis, this figure was 18.5% for squamous cell carcinoma and the majority were diagnosed at stages III and IV ([Table 1](#T1){ref-type="table"}).

Tumour stage is a very important predictor of survival ([Fig.2](#F2){ref-type="fig"}). The higher the stage of the tumour is at the time of diagnosis, the lower the survival. Our finding of the effect of stage on survival was in complete agreement with the existing literature ([@R18],[@R20],[@R24]).
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Age was a significant predictor of survival in univariate analysis in our study. Similar findings have been reported by many researchers ([@R18],[@R20],[@R25]), although, some did not find any association between age, sex and survival ([@R26]). In the current study, men survived slightly longer than women although the association was not significant. There are other studies that have found similar results regarding gender, but the bulk of literature does not support this finding. In these studies,womenhave a longersurvival than men ([@R18]-[@R20],[@R27]-[@R30]).

Living in a rural area put people in a disadvantaged position regarding skin cancer survival. In the current study 44% of patients living in the urban areas were diagnosed in stage 1 and 2 while the corresponding figure for residents of rural areas was 27%. Access to the healthcare facilities and therefore delay in seeking medical attention could explain this difference. Risk of death was lower in literate people compared with illiterate that could also originate from delay in asking medical advice.

More than 24 months delay in diagnosis could double the risk although it did not reach statistical significance. Delay in diagnosis increases the stage of tumour at the time of diagnosis and therefore could be an important factor in survival. However we did not find any association between the two that might reflect the retrospective design of this study and subsequent limitations in collecting accurate information on the actual amount of delay time.

Our study has some strengths and limitations. Accurate recording of time and cause of death as we had access to registrar office in Kurdistan province and cross checked the information in our interviews. On the other hand, we were unable to ascertain stage in some patients as we could not access all necessary data. Furthermore we only followed those patients who had their contact details recorded in their registry file. This may result in exclusion of some disadvantaged people from our study. However, comparison between characteristics of interviewed subjects with the rest of the skin cancers registered in Kurdistan Cancer Registry ([Table 4](#T4){ref-type="table"}) showed no considerable difference between the two populations. Future studies with a prospective design could address this limitation and provide a more accurate estimate of survival.

Adopting some strategies towards prevention, and timely diagnosis and treatment could help reduce the burden of the disease particularly in rural areas. An important first step is a public education campaign about causes of skin cancer particularly in those who are exposed to sun light for long hours such as farmers. In any educational campaign in rural areas it is also helpful to get help from institutions which are not directly involved in heath matters but are an important point of access for farmers such as those that provide agricultural advice and equipment. Educating women about ways of prevention and early signs of skin cancer is another important step particularly in rural areas. Finally, encouraging family physicians for timely referral of patients to specialist could help with effective treatment.

In summary our study showed that survival from skin cancer in Kurdistan province is worse than most global figures and therefore in need of urgent attention. We found that delay in diagnosis is an important contributor to this problem. Effective public health campaign about preventive measures particularly from sun exposure and early signs of disease for timely diagnosis and treatment could tackle the problem in long term and increase the survival indicators in Iranian patients.
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